不同因素对尿毒症患者前臂自体动静脉内瘘初次失功的影响
The Effect of Different Factorson the Initial Dysfunction of Forearm Arteriovenous Fistula in Uremia Patients
DOI: 10.12677/ACM.2020.104082, PDF,    科研立项经费支持
作者: 崔天元, 孔祥雷, 杨 洋, 李文斌：山东第一医科大学附属千佛山医院肾病学科，山东 济南
关键词: 尿毒症；自体动静脉内瘘；血磷；叶酸；他汀类药物；阿司匹林；RAAS阻断剂；Uremia； Arteriovenous Fistula； Serum Phosphorus； Folic Acid； Statins； Aspirin； RAAS Blocker
摘要: 目的：探讨不同因素对尿毒症患者前臂自体动静脉内瘘(AVF)初次失功的影响。方法：回顾性分析从本院选取336名行前臂AVF (手术方式桡动脉与头静脉端侧吻合，动静脉直径均>2 mm)的成年尿毒症患者的一般临床资料、用药情况等，采用Kaplan-Meier生存曲线分析不同药物治疗组AVF的生存差异，Cox多因素回归模型分析AVF失功的危险因素。结果：在纳入研究的患者中，有72例(21.4%)患者发生了AVF的失功，12个月及24个月时AVF的通畅率分别为78.0%和66.0%。AVF失功组与通畅组相比，两组之间在年龄、性别、用药情况等指标上均无统计学差异，但是AVF失功组血磷水平明显高于通畅组[2.03 (1.68~2.29) vs. 1.69 (1.38~2.12) mmol/L, P = 0.01]。结论：血磷升高为AVF失功的独立危险因素。
Abstract: Objective: To explore the effect of different factors on the initial dysfunction of forearm arteriovenous fistula in uremia patients. Methods: The general clinical data and medications of 336 adult uremic patients with forearm AVF (The radial artery and cephalic vein were anastomosed end to side, and the diameter of the artery and vein was more than 2 mm) from our hospital were studied by retrospective analysis. The survival times of overall and different groups were evaluated by the Life table and Kaplan-Meier curves. Multivariable Cox regression analysis was used to study the factors associated with the dysfunction of AVF. Results: Among the patients included in the study, 72 (21.4%) had AVF dysfunction, and the patency rate of AVF was 78.0% and 66.0% at 12 and 24 months, respectively. There was no significant difference in age, gender and drug use be-tween the two groups, but the level of the serum phosphorus in AVF group was significantly higher than that in normal group [2.03 (1.68 - 2.29) vs. 1.69 (1.38 - 2.12) mmol/L, P = 0.01]. Conclusions: The increase of the serum phosphorus was an independent risk factor for AVF failure.
文章引用：崔天元, 孔祥雷, 杨洋, 李文斌. 不同因素对尿毒症患者前臂自体动静脉内瘘初次失功的影响[J]. 临床医学进展, 2020, 10(4): 520-529. https://doi.org/10.12677/ACM.2020.104082

参考文献

[1] Zhang, L., Wang, F., Wang, L., et al. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 379, 815-822. [Google Scholar] [CrossRef] 
[2] Bylsma, L.C., Gage, S.M., Reichert, H., et al. (2017) Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-Analysis of Effi-cacy and Safety Outcomes. European Journal of Vascular and Endovascular Surgery, 54, 513-522. [Google Scholar] [CrossRef] [PubMed]
[3] Sheth, R.A., Freed, R., Tavri, S., et al. (2017) Nonmaturing Fis-tulae: Epidemiology, Possible Interventions, and Outcomes. Techniques in Vascular and Interventional Radiology, 20, 31-37. [Google Scholar] [CrossRef] [PubMed]
[4] Schinstock, C.A., Albright, R.C., Williams, A.W., et al. (2011) Outcomes of Arteriovenous Fistula Creation after the Fistula First Initiative. Clinical Journal of the American Society of Nephrology, 6, 1996-2002. [Google Scholar] [CrossRef] 
[5] Levey, A.S., Stevens, L.A., Schmid, C.H., et al. (2009) A New Equa-tion to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 150, 604-612. [Google Scholar] [CrossRef] [PubMed]
[6] Kong, X., Ma, Y., Chen, J., et al. (2013) Evalu-ation of the Chronic Kidney Disease Epidemiology Collaboration Equation for Estimating Glomerular Filtration Rate in the Chinese Population. Nephrology Dialysis Transplantation, 28, 641-651. [Google Scholar] [CrossRef] [PubMed]
[7] 金其庄, 王玉柱, 叶朝阳, 等. 中国血液透析用血管通路专家共识(第2版)[J]. 中国血液净化, 2019, 18(6): 365-381.
[8] Chang, A.R. and Anderson, C. (2017) Dietary Phosphorus Intake and the Kidney. Annual Review of Nutrition, 37, 321-346. [Google Scholar] [CrossRef] [PubMed]
[9] Schiavi, S.C. and Kumar, R. (2004) The Phosphatonin Pathway: New Insights in Phosphate Homeostasis. Kidney International, 65, 1-14. [Google Scholar] [CrossRef] [PubMed]
[10] Bellasi, A., Mandreoli, M., Baldrati, L., et al. (2011) Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dys-function. Clinical Journal of the American Society of Nephrology, 6, 883-891. [Google Scholar] [CrossRef] 
[11] Scialla, J.J. and Wolf, M. (2014) Roles of Phosphate and Fibroblast Growth Factor 23 in Cardiovascular Disease. Nature Reviews Nephrology, 10, 268-278. [Google Scholar] [CrossRef] [PubMed]
[12] Da, J., Xie, X., Wolf, M., et al. (2015) Serum Phosphorus and Pro-gression of CKD and Mortality: A Meta-Analysis of Cohort Studies. American Journal of Kidney Diseases, 66, 258-265. [Google Scholar] [CrossRef] [PubMed]
[13] Hu, M.C., Shiizaki, K., Kuro-o, M., et al. (2013) Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annual Review of Physiology, 75, 503-533. [Google Scholar] [CrossRef] [PubMed]
[14] Shimada, T., Hasegawa, H., Yamazaki, Y., et al. (2004) FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis. Journal of Bone and Mineral Research, 19, 429-435. [Google Scholar] [CrossRef] 
[15] Hruska, K.A., Sugatani, T., Agapova, O., et al. (2017) The Chronic Kidney Disease—Mineral Bone Disorder (CKD-MBD): Advances in Pathophysiology. Bone, 100, 80-86. [Google Scholar] [CrossRef] [PubMed]
[16] Baum, M., Schiavi, S., Dwarakanath, V., et al. (2005) Effect of Fibroblast Growth Factor-23 on Phosphate Transport in Proximal Tubules. Kidney International, 68, 1148-1153. [Google Scholar] [CrossRef] [PubMed]
[17] Ewence, A.E., Bootman, M., Roderick, H.L., et al. (2008) Calcium Phosphate Crystals Induce Cell Death in Human Vascular Smooth Muscle Cells: A Potential Mechanism in Atherosclerotic Plaque Destabilization. Circulation Research, 103, e28-e34. [Google Scholar] [CrossRef] 
[18] Viegas, C.S., Rafael, M.S., Enriquez, J., et al. (2015) Gla-Rich Protein Acts as a Calcification Inhibitor in the Human Cardiovascular System. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 399-408. [Google Scholar] [CrossRef] 
[19] Kapustin, A.N., Davies, J.D., Reynolds, J.L., et al. (2011) Calcium Regulates Key Components of Vascular Smooth Muscle Cell-Derived Matrix Vesicles to Enhance Minerali-zation. Circulation Research, 109, e1-e12. [Google Scholar] [CrossRef] 
[20] Chatrou, M.L., Cleutjens, J.P., van der Vusse, G.J., et al. (2015) Intra-Section Analysis of Human Coronary Arteries Reveals a Potential Role for Micro-Calcifications in Mac-rophage Recruitment in the Early Stage of Atherosclerosis. PLoS ONE, 10, e0142335. [Google Scholar] [CrossRef] [PubMed]
[21] Cohen, S.D., Phillips, T.M., Khetpal, P., et al. (2010) Cytokine Patterns and Survival in Haemodialysis Patients. Nephrology Dialysis Transplantation, 25, 1239-1243. [Google Scholar] [CrossRef] [PubMed]
[22] Yamada, S. and Giachelli, C.M. (2017) Vascular Calcification in CKD-MBD: Roles for Phosphate, FGF23, and Klotho. Bone, 100, 87-93. [Google Scholar] [CrossRef] [PubMed]
[23] Belmokhtar, K., Ortillon, J., Jaisson, S., et al. (2019) Receptor for Advanced Glycation end Products: A Key Molecule in the Genesis of Chronic Kidney Disease Vascular Calcification and a Potential Modulator of Sodium Phosphate Co-Transporter PIT-1 Expression. Nephrology Dialysis Transplantation, 34, 2018-2030. [Google Scholar] [CrossRef] [PubMed]
[24] Belmokhtar, K., Robert, T., Ortillon, J., et al. (2016) Signaling of Serum Amyloid a through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Ath-erosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 800-809. [Google Scholar] [CrossRef] 
[25] Aleshin, A., Ananthakrishnan, R., Li, Q., et al. (2008) RAGE Modulates Myocardial Injury Consequent to LAD Infarction via Impact on JNK and STAT Signaling in a Murine Model. The American Journal of Physiology—Heart and Circulatory Physiology, 294, H1823-H1832. [Google Scholar] [CrossRef] [PubMed]
[26] Chavkin, N.W., Chia, J.J., Crouthamel, M.H., et al. (2015) Phosphate Uptake-Independent Signaling Functions of the Type III Sodium-Dependent Phosphate Transporter, PiT-1, in Vascular Smooth Muscle Cells. Experimental Cell Research, 333, 39-48. [Google Scholar] [CrossRef] [PubMed]
[27] Coleman, C.I., Tuttle, L.A., Teevan, C., et al. (2010) Antiplatelet Agents for the Prevention of Arteriovenous Fistula and Graft Thrombosis: A Meta Analysis. International Journal of Clinical Practice, 64, 1239-1244. [Google Scholar] [CrossRef] [PubMed]
[28] Pisoni, R., Barker-Finkel, J. and Allo, M. (2010) Statin Therapy Is Not Associated with Improved Vascular Access Outcomes. Clinical Journal of the American Society of Nephrology, 5, 1447-1450. [Google Scholar] [CrossRef] 
[29] Martinez, L., Duque, J.C., Escobar, L.A., et al. (2016) Distinct Impact of Three Different Statins on Arteriovenous Fistula Outcomes: A Retrospective Analysis. The Journal of Vascular Access, 17, 471-476. [Google Scholar] [CrossRef] [PubMed]
[30] Irish, A.B., Viecelli, A.K., Hawley, C.M., et al. (2017) Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial. JAMA Internal Medicine, 177, 184-193. [Google Scholar] [CrossRef] [PubMed]
[31] Chen, Y.W., Wu, Y.T., Lin, J.S., et al. (2016) Association of Genetic Polymorphisms of Renin-Angiotensin-Aldosterone System-Related Genes with Arterio-Venous Fistula Malfunction in Hemodialysis Patients. International Journal of Molecular Sciences, 17, 833. [Google Scholar] [CrossRef] [PubMed]
[32] Moon, J.Y., Jeong, K.H., Paik, S.S., et al. (2009) Arteriovenous Fistula Patency Associated with Angiotensin-Converting Enzyme I/D Polymorphism and ACE Inhibition or AT1 Receptor Blockade. Nephron Clinical Practice, 111, c110-c116. [Google Scholar] [CrossRef] [PubMed]
[33] Kong, X., Ma, X., Zhang, C., et al. (2017) Hyperhomocysteinemia Increases the Risk of Chronic Kidney Disease in a Chinese Middle-Aged and Elderly Population-Based Cohort. International Urology and Nephrology, 49, 661-667. [Google Scholar] [CrossRef] [PubMed]
[34] Yi, F. and Li, P.L. (2008) Mechanisms of Homocysteine-Induced Glomerular Injury and Sclerosis. American Journal of Nephrology, 28, 254-264. [Google Scholar] [CrossRef] [PubMed]
[35] Tai, H.C., Yang, W.C., Chen, T.W., et al. (2005) Are Homocysteine and MTHFR Genotype Polymorphism Associated with Arteriovenous Fistula Patency. American Journal of Kidney Diseases, 46, 993-994. [Google Scholar] [CrossRef] [PubMed]
[36] Righetti, M., Ferrario, G., Serbelloni, P., et al. (2009) Some Old Drugs Improve Late Primary Patency Rate of Native Arteriovenous Fistulas in Hemodialysis Patient. Annals of Vascular Surgery, 23, 491-497. [Google Scholar] [CrossRef] [PubMed]
[37] Kong, X., Zhang, L., Zhang, L., et al. (2012) Mineral and Bone Disorder in Chinese Dialysis Patients: A Multicenter Study. BMC Nephrology, 13, 116. [Google Scholar] [CrossRef] [PubMed]
[38] Nitta, K., Akiba, T., Uchida, K., et al. (2003) The Progression of Vascular Calcification and Serum Osteoproteger in Levels in Patients on Long-Term Hemodialysis. American Journal of Kidney Diseases, 42, 303-309. [Google Scholar] [CrossRef] 
[39] Ekim, M., Yüksel, S., Fit?z, S., et al. (2006) Systemic Vascular Calcification with Retinal Calcification in an Adolescent Treated with Long-Term Peritoneal Dialysiy. Pediatric Nephrology, 21, 1915-1916. [Google Scholar] [CrossRef] [PubMed]
[40] Jin, C.S., Eun, Y.H., Soo, K.Y., et al. (2015) Pre-Existing Arterial Micro-Calcification Predicts Primary Unassisted Arteriovenous Fistula Failure in Incident Hemodialysis Patients. Seminars in Dialysis, 28, 665-669. [Google Scholar] [CrossRef] [PubMed]
[41] Young, L.J. and Ok, K.Y. (2017) Pre-Existing Arterial Pathologic Changes Affecting Arteriovenous Fistula Patency and Cardiovascular Mortality in Hemodialysis Patients. The Korean Journal of Internal Medicine, 32, 790-797. [Google Scholar] [CrossRef] [PubMed]

为你推荐